PCM
AMRX icon

Prelude Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Prelude Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$177K Buy
+14,210
New +$191K 0.01% 940
2025
Q4 		– Sell
-13,801
Closed -$138K – 1281
2025
Q3 		$138K Sell
13,801
-24,322
-64% -$218K 0.01% 1014
2025
Q2 		$308K Buy
38,123
+25,030
+191% +$189K 0.03% 601
2025
Q1 		$110K Buy
13,093
+2,349
+22% +$19.6K 0.01% 1028
2024
Q4 		$85.1K Buy
+10,744
New +$90.1K 0.01% 1108
2024
Q2 		– Sell
-10,841
Closed -$65.7K – 1202
2024
Q1 		$65.7K Buy
+10,841
New +$61.1K ﹤0.01% 1236
2023
Q1 		– Sell
-12,562
Closed -$25K – 1161
2022
Q4 		$25K Buy
+12,562
New +$28.2K ﹤0.01% 1169
2021
Q1 		– Sell
-338,426
Closed -$1.55M – 1513
2020
Q4 		$1.55M Buy
338,426
+64,454
+24% +$286K 0.04% 363
2020
Q3 		$1.06M Buy
273,972
+132,130
+93% +$565K 0.05% 267
2020
Q2 		$675K Sell
141,842
-75,000
-35% -$309K 0.04% 403
2020
Q1 		$755K Buy
+216,842
New +$918K 0.05% 255
2019
Q3 		– Sell
-1,300
Closed -$9K – 1689
2019
Q2 		$9K Buy
+1,300
New +$13.3K ﹤0.01% 1414
2018
Q3 		– Sell
-1,341
Closed -$22K – 1709
2018
Q2 		$22K Buy
+1,341
New +$23.5K ﹤0.01% 1331

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Prelude Capital Management's AMRX Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Amneal Pharmaceuticals (AMRX) in Q1 2026: 14,210 shares worth $177K. The stake represents 0.01% of the portfolio and ranks #940 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in AMRX as recently as Q3 2025.

Prelude Capital Management first reported a position in AMRX in Q2 2018 and has held it in 13 quarters since. The position peaked at $1.55M in Q4 2020. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Prelude Capital Management held 14,210 shares of Amneal Pharmaceuticals worth $177K as of Q1 2026.
  • Amneal Pharmaceuticals was a new Prelude Capital Management position in Q1 2026.
  • Amneal Pharmaceuticals made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #940 holding.
  • Prelude Capital Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 13 quarters since.
  • Prelude Capital Management's Amneal Pharmaceuticals position peaked at $1.55M in Q4 2020.
  • 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.